In a large multicenter cohort, dual antiplatelet therapy showed the greatest 90 day benefit when started within 24 hours ...
Early dual antiplatelet therapy shows superior efficacy in reducing stroke recurrence compared with aspirin monotherapy.
In patients who require a valve-in-valve (ViV) transcatheter procedure for a failed aortic bioprosthesis, the choice of antiplatelet therapy has little bearing on major ischemic and bleeding outcomes ...
In certain patients with mild-to-moderate acute ischemic stroke, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (Plavix) reduced early neurologic deterioration better than aspirin alone ...
Investigators analyzed pooled data from two randomized, double-blind, placebo-controlled clinical trials in China of patients with MIS or HRTIA who were receiving DAPT. Patients (n = 7440, median age, ...
(DAPT) in patients treated with Firehawk stents was non-inferior to 12 months of DAPT for the primary composite event of all-cause death, myocardial infarction, cerebrovascular accident and major ...
PARIS, France—Three-year findings from the HOST-IDEA trial continue to support a strategy of shorter-duration dual antiplatelet therapy (DAPT) following PCI with contemporary, ultrathin-strut ...
The interest in dual antiplatelet therapy after valve-in-valve transcatheter aortic valve intervention stems from the higher thrombotic risk associated with reintervention for a bioprosthetic valve ...
Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However ...
MADRID — The benefits of and risks for dual antiplatelet therapy (DAPT) after percutaneous coronary intervention do not appear to be one-size-fits-all, according to two large studies. Data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback